Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Healthy
- Sponsor
- Stanford University
- Primary Endpoint
- Plasma GnRH levels resulting from hypothalamus activation via LC-MS
- Status
- Withdrawn
- Last Updated
- 4 years ago
Overview
Brief Summary
This study is investigating brain regions that share functional connectivity with the hypothalamus and the stimulation of those regions using repetitive transcranial magnetic stimulation (rTMS) to activate the hypothalamus indirectly. The goal of this study is to determine the effectiveness of rTMS in influencing the hypothalamus to better understand the mechanisms between it and the neuroendocrine processes it controls.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age: 21-55
- •Gender: Females and Males
- •Weight: Less than 280 pounds
- •Normal vision with corrective lenses if necessary
- •Fluent in English (written and spoken)
Exclusion Criteria
- •History of epilepsy/seizures (including history of withdrawal/provoked seizures)
- •Metal implant in brains (e.g. deep stimulation), cardiac pacemaker, or cochlear implants
- •Shrapnel or any ferromagnetic item in the head
- •Showing symptoms of withdrawal from alcohol or benzodiazepines
- •Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation)
- •Migraine or significant headaches
- •Shoulder or neck stiffness
- •Over 280 pounds
- •In-dwelling ferrous metals
- •Left handed
Outcomes
Primary Outcomes
Plasma GnRH levels resulting from hypothalamus activation via LC-MS
Time Frame: 3 hours
Measure levels of the gonadotropin-releasing hormone (GnRH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma oxytocin levels via LC-MS
Time Frame: 3 hours
Measure levels of the oxytocin hormone in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma vasopressin levels via LC-MS
Time Frame: 3 hours
Measure levels of the vasopressin hormone in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma TRH levels via LC-MS
Time Frame: 3 hours
Measure levels of the thyrotropin-releasing hormone (TRH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma ACTH levels via LC-MS
Time Frame: 3 hours
Measure levels of the adrenocorticotropic hormone (ACTH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma CRH levels via LC-MS
Time Frame: 3 hours
Measure levels of the corticotropin-releasing hormone (CRH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma somatostatin levels via LC-MS
Time Frame: 3 hours
Measure levels of the somatostatin hormone, or growth hormone-inhibiting hormone (GHIH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma FSH levels via LC-MS
Time Frame: 3 hours
Measure levels of the follicle-stimulating hormone (FSH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma cortisol levels via LC-MS
Time Frame: 3 hours
Measure levels of the cortisol hormone in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma PRLH levels via LC-MS
Time Frame: 3 hours
Measure levels of the prolactin-releasing hormone (PRLH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Plasma LH levels via LC-MS
Time Frame: 3 hours
Measure levels of the luteinizing hormone (LH) in blood plasma through liquid chromatography-mass spectrometry (LC-MS) resulting from hypothalamus and neuroendocrine activation
Secondary Outcomes
- Heart rate via pulse oximeter(3 hours)
- Blood pressure via sphygmomanometer(3 hours)